Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen

References

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
   Google Scholar
• Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid subcategories)–a Southwest Oncology Group Study. Blood 1995;85:1075–1082.
   PubMed Web of Science ®Google Scholar
• Angelopoulou MK, Kontopidou F, Pangalis GA. Mantle cell lymphoma. Clinical features, diagnosis, biology treatment and prognosis. In: Pangalis GA, editor. ESO Monographs. Malignant lymphomas: biology and treatment. An update. Berlin: Springer; 1995. pp 143–149.
   Google Scholar
• Argatoff LH, Connors JM, Klassa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067–2078.
   PubMed Web of Science ®Google Scholar
• Oinonen R, Franssila K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998;34:329–336.
   PubMed Web of Science ®Google Scholar
• Brittinger G, Bartels H, Common H, et al. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas: results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 1984;2:269–306.
   PubMedGoogle Scholar
• Schrader C, Meusers P, Brittinger G, et al. Topoisomerase II alpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 2004;18:1200–1206.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Vassilakopoulos TP. Topoisomerase IIa as a prognostic factor in mantle cell lymphoma. Leukemia 2004;18:1347–1349.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. European Mantle Cell Lymphoma Network: a new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Blood 2008;111:558–565.
   Google Scholar
• Angelopoulou MK, Siakantaris MP, Vassilakopoulos TP, Kontopidou FN, Rassidakis GZ, Dimopoulou MN, et al. The splenic form of mantle cell lymphoma. Eur J Haematol 2002;68:12–21.
   PubMed Web of Science ®Google Scholar
• Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996;87:4302–4310.
   PubMed Web of Science ®Google Scholar
• Nicolle A, Proctor SJ, Summerfield GP. High dose chlorambucil in the treatment of lymphoid malignancies. Leuk Lymphoma 2004;45:271–275.
   PubMed Web of Science ®Google Scholar
• Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317–324.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;4:235–242.
   Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti S, et al. Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005;23:705–711.
   PubMed Web of Science ®Google Scholar
• Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, et al. Immunotherapeutic and immunoregulatory drugs in haematologic malignancies. Curr Top Med Chem 2006;6:1657–1686.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007;25:127–131.
   PubMed Web of Science ®Google Scholar
• Coleman M, Martin P, Ruan J, et al. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma 2008;49:447–450.
   PubMed Web of Science ®Google Scholar
• Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002;87:33–43.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257–2317.
   PubMed Web of Science ®Google Scholar
• Determann O, Hoster E, Ott G, et al. European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385–2387.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257–262.
   PubMed Web of Science ®Google Scholar
• Velders GA, Kluin-Nelemans JC, De Boer CJ, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996;14:1269–1274.
   PubMed Web of Science ®Google Scholar
• Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G, et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997;99:842–847.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
   PubMed Web of Science ®Google Scholar
• Epner EM, Unger J, Miller T, et al. A multicenter trial of hyperCVAD + rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 2007;110(Suppl. 1): Abstract 387.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677–2684.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008;19:1327–1330.
   PubMed Web of Science ®Google Scholar
• Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Dimopoulou MN, Siakantaris MP, Kontopidou FN, et al. Anti-CD20 monoclonal antibody administration post chlorambucil in MCL patients lead to eradication of minimal residual disease. Blood 2000;96(Suppl. 1): Abstract 236b.
   Google Scholar
• Bauwens D, Maerevoet M, Michaux L, et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol 2005;131:338–340.
   PubMed Web of Science ®Google Scholar
• Gressin R, Caulet-Maugendre S, Deconinck E, et al. Evaluation of the (R)VAD + C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 2010;95:1350–1357.
   Google Scholar
• Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010;115:3215–3223.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al. German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003–4008.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:1418–1423.
   PubMed Web of Science ®Google Scholar